EPISEEK™ Multi-Cancer Early Detection
Invest in your patients’ health.
The Precision Epigenomics liquid biopsy test, EPISEEK™, is a blood-based test designed to accurately assess DNA shed by tumors called “circulating tumor DNA” (ctDNA). EPISEEK™ detects cancer-specific aberrant DNA methylation cell-free DNA, targeting a proprietary set of biomarkers that reliably indicate the presence of cancer (this molecular signature is not found in normal cells).
Using advanced technology software, epigenomic modifications are analyzed. This technology is cost-effective, precise, minimally invasive, and may detect cancer earlier than imaging. It is also more accessible than a tissue biopsy.
The EPISEEK™ Tests Detects All Major Cancer Types
Brain
Lung & Bronchus
Breast
Colon & Rectum
Prostate
Melanoma
Bladder
Kidney
Pancreas
Lymphoma
Uterine and Cervical
Thyroid
Oral
Liver
Esophagus
Ovarian
Feel in Control of Your Health.
Talk to your healthcare professional about scheduling your EPISEEK™ early cancer detection test.
%
5-Year Survival Rate
when cancer is detected early*
The Right Provider is Committed to Keeping You Healthy.
“As a physician, I know that early detection is critical in the fight against cancer. The EPISEEK™ liquid biopsy test is a groundbreaking tool that identifies cancer at its earliest stages, when it’s most treatable. I highly recommend Precision Epigenomics for its accuracy and its potential to save lives by catching cancer before symptoms begin. Not only do I order EPISEEK™ for my patients, but my healthcare provider also ordered it for me.”
– KRISTINE ROMINE, MD
More than just an early cancer detection test.
It’s peace of mind.
Using a specificity of 99%, EPISEEK is predicted to have a positive predictive value (PPV) of 40% and a negative predictive value (NPV) of 99% in patients 50 years and older.
For aggressive Stages I & II cancers that do not have widely adopted screening, such as bladder, esophagus, liver, head and neck SCC, lung, pancreas, stomach, and uterus, EPISEEK has a sensitivity of 57%. For Stage III cancer, which is still operable in many cases, the sensitivity is 73%.